Response to the Antibody Reproducibility Crisis

An article from the May issue of  Nature entitled: Reproducibility Crisis: Blame it on the Antibodies was shared and circulated widely in biotechnology forums and social media platforms.  The widespread interest in the article speaks to the commonly shared industry frustration over antibodies not performing well in end use assays. The explosion of genomic and proteomic medicine over the last few decades has indeed created an insurmountable challenge for the antibody retail sales model. The rapid growth of the number of antibody targets of interest, combined with increasingly nuanced desired epitopes, makes having a comprehensive, well supported catalog nearly impossible.
Read More

Categories: Industry News, New Products, News, and Services.

MBS is exhibiting AACC Clinical Lab Expo in Atlanta, Georgia July 26-30 2015

MBS is exhibiting at the 2015 AACC Clinical Lab Expo in Atlanta, Georgia July 26-30.  MBS is celebrating 25 years in business in 2015. Stop by booth #3758 to discuss your antibody and assay goals with our technical sales team or browse our antibody product catalog.  Our mission is to go beyond limited contract services and be a comprehensive partner in antibody and assay method development.  MBS saves customers money and compresses timelines of the most complex projects.  The cornerstone of antibody and assay development at MBS is our technical team approach to project design and planning. The MBS antibody development plan focuses
Read More

Categories: Industry News, New Products, News, and Services.

25th Year at MBS

(PRWEB) June 09, 2015 Maine Biotechnology Services, a premier provider of antibody based services is celebrating its 25th year in business. In 1990, Dr. Joseph Chandler founded MBS with the intent to be true partners to life science researchers in their pursuit of ideal antibodies for any application. Over the course of 25 years, MBS has delivered on that promise, adding broad and deep technical expertise in antibody and assay related technologies. MBS serves customers in a dynamic marketplace where timely assay performance is paramount to pharmaceutical and diagnostic development. Continual investment into tools, protocols, and process development have kept
Read More

Categories: News and Press Releases.

MBS-UNC Partnership Provides Monoclonal Antibodies to Aid in the Diagnosis of Chikungunya Virus

Today, MBS is announcing the release of three monoclonal antibodies to chikungunya virus. All three antibodies detect active strains of chikungunya virus by ELISA Portland, Maine (PRWEB) January 08, 2015 In 2012 Maine Biotechnology Services entered into a partnership with Drs. Mark Heise and Kristin Long of the University of North Carolina Medical School, with the objective of developing monoclonal antibodies to support ongoing research efforts to advance adequate vaccine and rapid detection methods for chikungunya virus (CHIKV), an emerging global infection. Today, MBS is announcing the release of three monoclonal antibodies resulting from that partnership. Inactivated CHIKV was used
Read More

Categories: News and Press Releases.

Monoclonal Antibodies to Chikungunya Virus

MBS is pleased to announce that 3 monoclonal antibodies specific to Chikungunya virus (CHIKV) are purified and ready for sampling.  MAB243P, MAB244P and MAB245P were developed in close partnership with Dr. Mark Heise and Dr. Kristen Long of the University of North Carolina School of Medicine.  Applications for these antibodies include the detection of active virus either in circulation or in mosquito carriers. In addition to recognizing the immunizing vaccine strain 181/25 by ELISA, these clones also show reactivity to a strain originating in Sri Lanka.  Further ELISA data indicates that the antibodies do not cross-react with other alphavirus infections
Read More

Categories: New Products and News.

Complete Panel of Norovirus Antibodies

Maine Biotechnology Services developed a comprehensive panel of antibodies specific for human Norovirus, including GII.4 2012 SYDNEY STRAIN.  There are currently five known genogroups, of which three cause human disease: GI, GII, and GIV.  According to the CDC, since 2002 GII.4 has been the most common cause of Norovirus outbreaks. All MBS Norovirus antibodies have been tested across a broad range of strains, as reported in the table below. MAB227P demonstrated the ability to block ligand binding in surrogate neutralization assays.  MAB228P, developed against GI.1 1968 virus like particles (VLPs), recognizes additional GI types. MAB242P, the most recently developed antibody, is
Read More

Categories: New Products, News, Press Releases, R&D Updates, and Uncategorized.

MBS Collaborator in the News – Ralph Baric on Controversial Research Policy

How A Tilt Toward Safety Stopped A Scientist’s Virus Research As cases of a worrisome respiratory virus continue to pop up in the Middle East, scientists who study it in the U.S. are struggling to understand how they’ll be affected by a government moratorium on certain kinds of experiments. One of those researchers is Ralph Baric, a virologist at the University of North Carolina School of Medicine in Chapel Hill. “Any virus that has pandemic potential, and that’s any respiratory virus that emerges from animals, is a major public health concern,” Baric says. And Middle East respiratory syndrome, or MERS,
Read More

Categories: Industry News, New Products, and News.

MBS Doubles Capacity for In Vitro Antibody Production

In response to customer demand, MBS has significantly expanded roller bottle production space to continue efficient order processing. Trust MBS to answer the critical questions for successful In Vitro antibody production: Do you have an appropriate sized cell bank? Are the media conditions optimized?  Is serum free media required? Are endotoxin and contaminating proteins (e.g. bovine IgG) important to avoid for your end use? Does QA validation require 3 lots? What are the final parameters required for final concentration, preservatives, and aliquot size ? What is your long term supply forecast? Contact us at 207-797-5454 or [email protected] to book your
Read More

Categories: New Products, News, and Services.

Recombinant Protein Expression Now Available at Maine Biotechnology Services

Portland Maine – Bacterial recombinant protein expression is now available as a service at Maine Biotechnology Services. When MBS develops recombinant antigen for a hybridoma development, the end use application of the antibodies is considered during every phase of antigen production. Maine Biotechnology Services is announcing the addition of Bacterial Recombinant Protein Expression and Purification services to compliment our complete antibody service offering, adding value and efficiency to custom antibody development with MBS. A typical recombinant antigen project at MBS will begin with a careful analysis of the protein sequence and characteristics to assess its suitability for bacterial expression. MBS
Read More

Categories: News and Press Releases.

GST Monoclonal Antibody – Glutathione S-transferase

MAB241P, a monoclonal antibody specific for GST-tag, is part of a growing list of MBS products aimed at assisting our customers in the detection of recombinant proteins.  MBS R&D developed the murine antibody using recombinant GST as an immunogen.  MAB241P was shown to recognize N or C terminal GST fusion proteins as well as recombinant GST protein in Western Blot.  The internal development and production of MAB241P allows MBS to maintain the highest quality standards and the ability to offer the lowest possible price. Buy MAB241P       • Applications: Validated in western blot • Reactivity: Recognizes free GST, C
Read More

Categories: New Products and News.